FDA Considers Expanding Testosterone Therapy for Low Libido
The FDA is exploring the expansion of testosterone therapy as a treatment for low libido, according to STAT News. The report also notes early animal data suggesting GLP-1 alternatives such as GIP-glucagon pathways may offer comparable effectiveness with better tolerability for obesity treatment, and flags psychedelics as another area of regulatory focus.
Advertisement: Article Inline